Evofem Biosciences (EVFM) Tops Q2 EPS by 14c

Evofem Biosciences (NASDAQ: EVFM) reported Q2 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $2.92 million.

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

You May Also Be Interested In

• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• Novocure's Optune Pax wins CE Mark for pancreatic cancer
• Logitech dips as BofA downgrades stock on demand outlook concerns